



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_353_24

You asked:

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

24.

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

20.

**Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)

R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)

R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)

Axicabtagene ciloleucel

Tisagenlecleucel

Epcoritamab

Loncastuximab tesirine

Glofitamab

Any other SACT

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Please see relevant treatments below:

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) – Less than 5.

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) – Eight (8).

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) – Less than 5.

Any other SACT – Less than 5.

Where the figures are less than 5, the exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

Axicabtagene ciloleucel (Yescarta)

Tisagenlecleucel

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Any other treatments

Zero.

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

CAR-T Therapy (E.g. Axicabtagene ciloleucel)

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Any other treatment

Please see relevant treatment below:

Any other treatment – Less than 5 (Please see Q2 – S40 applied).

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

No active trials.